These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 24717110)

  • 1. Complete remission of CD30-positive diffuse large B-cell lymphoma in a patient with post-transplant lymphoproliferative disorder and end-stage renal disease treated with single-agent brentuximab vedotin.
    Hill BT; Tubbs RR; Smith MR
    Leuk Lymphoma; 2015 May; 56(5):1552-3. PubMed ID: 24717110
    [No Abstract]   [Full Text] [Related]  

  • 2. New frontiers for brentuximab vedotin for lymphomas.
    Moskowitz AJ
    Leuk Lymphoma; 2015 Feb; 56(2):283-4. PubMed ID: 25315080
    [No Abstract]   [Full Text] [Related]  

  • 3. CD30 in pediatric post-transplant lymphoproliferative disease after solid organ transplant: characterization of a new therapeutic target.
    Schober T; Framke T; Großhennig A; Klein C; Kreipe H; Maecker-Kolhoff B
    Leuk Lymphoma; 2015 Mar; 56(3):832-3. PubMed ID: 25242095
    [No Abstract]   [Full Text] [Related]  

  • 4. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.
    Jacobsen ED; Sharman JP; Oki Y; Advani RH; Winter JN; Bello CM; Spitzer G; Palanca-Wessels MC; Kennedy DA; Levine P; Yang J; Bartlett NL
    Blood; 2015 Feb; 125(9):1394-402. PubMed ID: 25573987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry.
    Bartlett NL; Smith MR; Siddiqi T; Advani RH; O'Connor OA; Sharman JP; Feldman T; Savage KJ; Shustov AR; Diefenbach CS; Oki Y; Palanca-Wessels MC; Uttarwar M; Li M; Yang J; Jacobsen ED
    Leuk Lymphoma; 2017 Jul; 58(7):1607-1616. PubMed ID: 27868471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD30: seeing is not always believing.
    Blum KA
    Blood; 2015 Feb; 125(9):1358-9. PubMed ID: 25721040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brentuximab vedotin as a single agent in the treatment of a pediatric primary cutaneous CD30
    Ceglie G; De Vito R; Cossutta M; Tiberi A; Carta R; Boccieri E; Palumbo G
    Pediatr Blood Cancer; 2022 Jun; 69(6):e29626. PubMed ID: 35322542
    [No Abstract]   [Full Text] [Related]  

  • 8. CD30 Expression in Monomorphic Posttransplant Lymphoproliferative Disorder, Diffuse Large B-Cell Lymphoma Correlates With Greater Regulatory T-Cell Infiltration.
    Hartley C; Vaughan JW; Jarzembowski J; Kroft SH; Hosking P; Harrington AM; Olteanu H
    Am J Clin Pathol; 2017 Nov; 148(6):485-493. PubMed ID: 29126177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas.
    Macalalad AR; McAuliffe M; Yang H; Kageleiry A; Zhong Y; Wu EQ; Shonukan O; Bonthapally V
    Curr Med Res Opin; 2015 Mar; 31(3):537-45. PubMed ID: 25598441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Occurrence and prognostic relevance of CD30 expression in post-transplant lymphoproliferative disorders.
    Vase MØ; Maksten EF; Bendix K; Hamilton-Dutoit S; Andersen C; Møller MB; Sørensen SS; Jespersen B; Kampmann J; Søndergård E; Nielsen PS; D'amore F
    Leuk Lymphoma; 2015 Jun; 56(6):1677-85. PubMed ID: 25248878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
    Scarisbrick JJ
    Future Oncol; 2017 Nov; 13(27):2405-2411. PubMed ID: 28805086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure.
    Necchi A; Anichini A; Raggi D; Giannatempo P; Magazzù D; Nicolai N; Colecchia M; Paolini B; Coradeschi E; Tassi E; Grazia G; Mortarini R; Calareso G; De Fato R; Togliardi E; Crippa F; Salvioni R; Valagussa P; Gianni AM
    Clin Genitourin Cancer; 2016 Aug; 14(4):261-264.e4. PubMed ID: 27105722
    [No Abstract]   [Full Text] [Related]  

  • 13. Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy.
    Gopal AK; Bartlett NL; Forero-Torres A; Younes A; Chen R; Friedberg JW; Matous JV; Shustov AR; Smith SE; Zain J; O'Meara MM; Fanale MA
    Leuk Lymphoma; 2014 Oct; 55(10):2328-34. PubMed ID: 24359243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.
    Bhatt G; Maddocks K; Christian B
    Curr Hematol Malig Rep; 2016 Dec; 11(6):480-491. PubMed ID: 27613003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphomas and lymphoproliferative disorders.
    Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 5):12-4. PubMed ID: 24852791
    [No Abstract]   [Full Text] [Related]  

  • 16. A treatment refractory CD30-positive diffuse large B cell lymphoma in the ileal neobladder.
    Ota S; Iwai T; Kawaji Y; Fujino T; Ohshiro M; Hirakawa Y; Chinen Y; Uchiyama H; Kaneko H; Kuroda J
    Ann Hematol; 2017 Apr; 96(4):683-684. PubMed ID: 28032185
    [No Abstract]   [Full Text] [Related]  

  • 17. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
    Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies.
    Prieto-Torres L; Rodriguez-Pinilla SM; Onaindia A; Ara M; Requena L; Piris MÁ
    Haematologica; 2019 Feb; 104(2):226-235. PubMed ID: 30630983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Implications of CD30 Expression in Aggressive B-Cell Lymphomas.
    Malysz J; Erdman P; Klapper J; Zhu J; Creer M; Bayerl MG
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):429-33. PubMed ID: 27521276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
    Oregel KZ; Everett E; Zhang X; Nagaraj G
    Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.